Episode Details

Cardinal Health just smashed it in Q4 and fiscal 2026, delivering strong growth across the board with its Pharma segment leading the charge. The company’s Global Medical Products division is turning around thanks to its improvement plan and a one-time tariff windfall, while other growth businesses are hitting double-digit profit gains. Executives praise consistent execution, solid demand, and record free cash flow — all fueling confidence for 13–15% EPS growth in 2027, backed by rising profits and revenue in key segments. They’re entering the new year with a resilient model and a clear focus on long-term value creation.

Listen in comfort:
Get a discount on a Soli Pillow: http://solipillow.com/discount/dnn.

Advertise on DNN:
advertise@thednn.ai

This is an automated, high-level news summary based on public reporting.
Report issues to feedback@thednn.ai.

View sources & latest updates:
https://sources.thednn.ai/97fdc87941b401b4